Stockscreener 앱 받기
4.89
5.60%
-0.29
시간 외 거래:
4.90
0.01
+0.20%
전일 마감가:
$5.18
열려 있는:
$5.17
하루 거래량:
1.45M
Relative Volume:
2.55
시가총액:
$463.97M
수익:
-
순이익/손실:
$-68.65M
주가수익비율:
-4.103
EPS:
-1.1918
순현금흐름:
$-64.93M
1주 성능:
-2.40%
1개월 성능:
-19.31%
6개월 성능:
+40.52%
1년 성능:
+300.82%
1일 변동 폭
$4.73
$5.2081
1주일 범위
$4.73
$5.50
52주 변동 폭
$0.98
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
명칭
Zura Bio Ltd
전화
858-247-0520
주소
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
4.89 | 491.48M | 0 | -68.65M | -64.93M | -1.1918 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | Wedbush | Outperform |
| 2024-11-04 | 개시 | Leerink Partners | Outperform |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2024-05-03 | 개시 | Piper Sandler | Overweight |
| 2023-10-10 | 개시 | Ladenburg Thalmann | Buy |
| 2023-08-25 | 개시 | Oppenheimer | Outperform |
| 2023-06-22 | 개시 | Guggenheim | Buy |
| 2023-06-14 | 개시 | Chardan Capital Markets | Buy |
| 2023-05-24 | 개시 | Raymond James | Strong Buy |
모두보기
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
JPMorgan reports 4.47M Zura Bio holdings (NASDAQ: ZURA) — 4.7% stake - Stock Titan
Zura Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Zura Bio | DEF 14A: Definitive information statements - Moomoo
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
[DEF 14A] Zura Bio Ltd Definitive Proxy Statement - Stock Titan
ZURA News | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio Limited 8-K Filing Details April 2026 – Separation Agreement, Company Information, and SEC Compliance - Minichart
Zura Bio LtdEric Hyllengren separated from Zura Bio Limited as CFO on April 20, 2026 - marketscreener.com
Zura Bio : Corporate Overview April 2026 (d9fec3) - marketscreener.com
Zura Bio Limited Announces CFO Changes, Effective April 20, 2026 - marketscreener.com
[8-K] Zura Bio Ltd Reports Material Event - Stock Titan
Jessica Chen - White & Case LLP
One Zura Bio Insider Raised Their Stake In The Previous Year - Yahoo Finance
JATT II Acquisition Corp Announces Closing of $60,000,000 Initial Public Offering - Benzinga
JATT Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
JATT Technical Analysis & Stock Price Forecast - Intellectia AI
JATT PE Ratio & Valuation, Is JATT Overvalued - Intellectia AI
JATT Forecast — Price Prediction for 2026. Should I Buy JATT? - Intellectia AI
Zura Bio Ltd stock (KYG989201089): Is its immunology pipeline strong enough to unlock biotech upside - AD HOC NEWS
Zura Bio Ltd stock: Why analysts see massive upside potential - AD HOC NEWS
Zura Bio (NASDAQ:ZURA) Shares Down 6.5%Here's What Happened - MarketBeat
Biotechnology executive pays $15 million for Pinecrest home (Photos) - The Business Journals
Zura Bio (ZURA) CTO awarded 263,000 share options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) CFO receives stock options for 340,900 shares at $6.03 - Stock Titan
Zura Bio grants 425,700 options to legal chief | ZURA Insider Trading - Stock Titan
Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares - Stock Titan
Chipmakers Recap: Is Zura Bio Limited a momentum stock2026 Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Fear: Will Zura Bio Limited benefit from rising consumer demandChart Signals & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - tradingview.com
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00 - Defense World
ZURA: Oppenheimer Lowers Price Target, Maintains Outperform Rati - GuruFocus
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Zura Bio Ltd expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zura Bio Ltd Aktie surges on positive Phase 2 data for autoimmune drug candidate - AD HOC NEWS
Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors - Minichart
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Ajay Nirula Net Worth (2026) - GuruFocus
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Ltd (ZURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.77%
0.25%
자본화:
|
볼륨(24시간):